Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy

被引:16
|
作者
Xiao, Yuchen [1 ,2 ]
Zhu, Tianchuan [1 ]
Zeng, Qi [3 ]
Tan, Qingqin [1 ]
Jiang, Guanmin [4 ]
Huang, Xi [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Infect & Immun, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Guangdong, Peoples R China
[2] Southern Marine Sci & Engn Guangdong Lab, Zhuhai 519000, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Oncol, Zhuhai 519000, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Clin Lab, Zhuhai 519000, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
PD-L1; Photothermal ablation; Biomimetic nanoparticles; Tumor microenvironment; Colorectal cancer; RESISTANCE;
D O I
10.1016/j.actbio.2022.11.043
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand pro-grammed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, including colorectal cancer. However, the efficacy of PD-1/PD-L1 inhibitors is limited in some colorec-tal cancers within the immunosuppressive tumor microenvironment (such as when there is a lack of immune cell infiltration). Herein, anti-PD-L1 functionalized biomimetic polydopamine-modified gold nanostar nanoparticles (PDA/GNS@aPD-L1 NPs) were developed for synergistic anti-tumor treatment by combining PD-1/PD-L1 blockade with photothermal ablation. PDA/GNS@aPD-L1 NPs were prepared by encapsulating photothermal nanoparticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane isolated from anti-PD-L1 single-chain variable fragment (scFv) over-expressing cells. In ad-dition to disrupting PD-1/PD-L1 immunosuppressive signals, the anti-PD-L1 scFv on the membrane of PDA/GNS@aPD-L1 NPs was conducive to the accumulation of PDA-GNS at tumor sites. Importantly, the tu-mor photothermal ablation induced by PDA-GNS could reverse the immunosuppressive tumor microenvi-ronment, thereby further improving the efficiency of PD-1/PD-L1 blockade therapy. In this study, the syn-thetized PDA/GNS@aPD-L1 NPs exhibited good biocompatibility, efficient photothermal conversion ability, and enhanced tumor-targeting ability. In vivo studies revealed that a PDA/GNS@aPD-L1 NP-based thera-peutic strategy significantly inhibited tumor growth, and prolonged overall survival by further promot-ing the maturation of dendritic cells (DCs), increasing the infiltration of CD8 + T cells, and decreasing the number of immunosuppressive cells (such as regulatory T cells and myeloid-derived suppressive cells). Collectively, the developed PDA/GNS@aPD-L1 NP-based therapeutic strategy combines PD-1/PD-L1 block-ade with photothermal ablation, which could remodel the tumor microenvironment for effective clinical colorectal cancer therapy.Statement of significance Immunosuppressive tumor microenvironment is the main challenge facing programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy. By encapsulating photothermal nanopar-ticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane over-expressing anti-PD -L1 single-chain variable fragment, we constructed anti-PD-L1 functionalized biomimetic nanoparticles (PDA/GNS@aPD-L1 NPs). By specific binding to the PD-L1 present on tumor cells, PDA/GNS@aPD-L1 NPs could disrupt PD-1/PD-L1 immunosuppression signaling, and effectively deliver PDA-GNS targeting to tu-mor sites. Additionally, PDA-GNS-mediated local photothermal ablation of tumors promoted the release of tumor-associated antigens and thus activated anti-tumor immune responses. Meanwhile, hyperthermia facilitates immune cell infiltration by increasing tumor vascular permeability. Therefore, PDA/GNS@aPD-L1 NPs could sensitize tumors to PD-1/PD-L1 blockade therapy by remodeling the immunosuppressive tumor microenvironment, which provides a new strategy for tumor treatment.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:451 / 466
页数:16
相关论文
共 50 条
  • [21] Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
    Grimm, M.
    Gasser, M.
    Koenigshausen, M.
    Stein, C.
    Lutz, J.
    Krol, S.
    Thiede, A.
    Heemann, U.
    Waaga-Gasser, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [23] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [24] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma (vol 27, pg 384, 2015)
    Cheah, C. Y.
    Fowler, N. H.
    Neelapu, S. S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (06) : 568 - 568
  • [25] Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold
    Qin, Mingze
    Cao, Qi
    Wu, Xia
    Liu, Chunyang
    Zheng, Shuaishuai
    Xie, Hongbo
    Tian, Ye
    Xie, Jun
    Zhao, Yanfang
    Hou, Yunlei
    Zhang, Xian
    Xu, Boxuan
    Zhang, Haotian
    Wang, Xiaobo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 186
  • [26] Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis
    Li, Xiaoyun
    Zeng, Qin
    Xu, Fengjiao
    Jiang, Yuying
    Jiang, Zhongmei
    MOLECULAR DIVERSITY, 2023, 27 (04) : 1935 - 1955
  • [27] Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review
    Caleb J. Smith
    Yahya Almodallal
    Aminah Jatoi
    Current Oncology Reports, 2021, 23
  • [28] Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis
    Xiaoyun Li
    Qin Zeng
    Fengjiao Xu
    Yuying Jiang
    Zhongmei Jiang
    Molecular Diversity, 2023, 27 : 1935 - 1955
  • [29] SAR study of small molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction
    Kawashita, Seiji
    Aoyagi, Koichi
    Fukushima, Kyoko
    Hantani, Rie
    Naruoka, Shiori
    Tanimoto, Atsuo
    Hori, Yuji
    Toyonaga, Yukiyo
    Yamanaka, Hiroshi
    Miyazaki, Susumu
    Hantani, Yoshiji
    CHEMICAL BIOLOGY & DRUG DESIGN, 2021, 98 (05) : 914 - 929
  • [30] Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
    Umran Kucukgoz Gulec
    Emine Kilic Bagir
    Semra Paydas
    Ahmet Baris Guzel
    Derya Gumurdulu
    Mehmet Ali Vardar
    Archives of Gynecology and Obstetrics, 2019, 300 : 377 - 382